Endotoxin, TLR4 signaling and vascular inflammation: Potential therapeutic targets in cardiovascular disease

Current Pharmaceutical Design

Volumn 12, Issue 32, 2006, Pages 4229-4245

  Stoll, Lynn L ^a   Denning, Gerene M ^a,b   Weintraub, Neal L ^c  

^a UNIVERSITY OF IOWA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

Atherogenesis; CD14 expression; Chemokines; Endotoxin; LPS Binding Protein (LPB); TLR4 receptor complex

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIBIOTIC AGENT; ATORVASTATIN; AZITHROMYCIN; CD14 ANTIGEN; CELL ADHESION MOLECULE; ENDOTOXIN; FLUINDOSTATIN; FREUND ADJUVANT; GERANYLGERANYL PYROPHOSPHATE; GLUCOSAMINE DERIVATIVE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEAT SHOCK PROTEIN 65; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; LIPOPOLYSACCHARIDE BINDING PROTEIN; MEVALONIC ACID; MEVINOLIN; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOID DIFFERENTIATION FACTOR 88; OXIDIZED LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROTEIN MD 2; ROSIGLITAZONE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; UNINDEXED DRUG; VACCINE;

ANTIBIOTIC THERAPY; ANTIINFLAMMATORY ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHRONIC INFLAMMATION; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG TARGETING; HUMAN; IMMUNE RESPONSE; INFECTION; INNATE IMMUNITY; MORBIDITY; NONHUMAN; PATHOGENESIS; POPULATION DISTRIBUTION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; VASCULITIS; WESTERN HEMISPHERE;

CARDIOVASCULAR DISEASES; CORONARY VESSELS; ENDOTOXINS; HUMANS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4;

EID: 33750537650     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206778743501     Document Type: Review

References (277)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-9.
2. de Boer OJ, van der Wal AC, Becker AE. Atherosclerosis, inflammation, and infection. J Pathol 2000; 190: 237-43.
3. Gerszten RE, Mach F, Sauty A, Rosenzweig A, Luster AD. Chemokines, leukocytes, and atherosclerosis. J Lab Clin Med 2000; 136(2): 87-92.
4. Glass CK, Witztum JL. Atherosclerosis: the road ahead. Cell 2001; 104: 503-16.
5. Libby P. inflammation in atherosclerosis. Nature 2002; 420(6917): 868-74.
6. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105(9): 1135-43.
7. Hansson GK, Libby P, Schonbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002; 91(4): 281-91.
8. Curtiss LK, Kubo N, Schiller NK, Boisvert WA. Participation of innate and acquired immunity in atherosclerosis. Immunol Res 2000; 21(2-3): 167-76.
9. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342(12): 836-43.
10. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003; 107(3): 391-7.
11. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352(16): 1685-95.
12. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation 2005; 111(25): 3481-8.
13. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340(2): 115-26.
14. Medzhitov R, Janeway C, Jr. Innate immunity. N Engl J Med 2000; 343(5): 338-44.
15. Uthaisangsook S, Day NK, Bahna SL, Good RA, Haraguchi S. Innate immunity and its role against infections. Ann Allergy Asthma Immunol 2002; 88(3): 253-64.
16. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 2001; 1(2): 135-45.
17. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002; 20: 197-216.
18. de Kleijn D, Pasterkamp G. Toll-like receptors in cardiovascular diseases. Cardiovasc Res 2003; 60(1): 58-67.
19. Cook DN, Pisetsky DS, Schwartz DA. Toll-like receptors in the pathogenesis of human disease. Nat Immunol 2004; 5(10): 975-9.
20. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4(7): 499-511.
21. Liew FY, Xu D, Brint EK, O'Neill LA. Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol 2005; 5(6): 446-58.
22. Stoll LL, Denning GM, Li WG, Rice JB, Harrelson AL, Romig SA, et al. Regulation of endotoxin-induced proinflammatory activation in human coronary artery cells: expression of functional membrane-bound CD14 by human coronary artery smooth muscle cells. J Immunol 2004; 173(2): 1336-43.
23. Stoll LL, Denning GM, Weintraub NL. Potential role of endotoxin as a proinflammatory mediator of atherosclerosis. Arterioscler Thromb Vase Biol 2004; 24(12): 2227-36.
24. Nilsson J. Regulating protective immunity in atherosclerosis. Circ Res 2005; 96(4): 395-7.
25. Nilsson J, Hansson GK, Shah PK. Immunomodulation of atherosclerosis: implications for vaccine development. Arterioscler Thromb Vasc Biol 2005; 25(1): 18-28.
26. Binder CJ, Chang W. Shaw PX, Miller YI, Hartvigsen K, Dewan A, et al. Innate and acquired immunity in atherogenesis. Nat Med 2002; 8(11): 1218-26.
27. Persing DH, Coler RN, Lacy MJ, Johnson DA, Baldridge JR, Hershberg RM, et al. Taking toll: lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol 2002; 10(10 Suppl): S32-7.
28. Jonasson L, Holm J, Skalli O, Bondjers G, Hansson GK. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis 1986; 6(2): 131-8.
29. Witztum JL. Splenic immunity and atherosclerosis: a glimpse into a novel paradigm? J Clin Invest 2002; 109(6): 721-4.
30. Michelsen KS, Doherty TM, Shah PK, Arditi M. TLR signaling: an emerging bridge from innate immunity to atherogenesis. J Immunol 2004; 173(10): 5901-7.
31. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003; 21: 335-76.
32. Underhill DM, Ozinsky A. Toll-like receptors: key mediators of microbe detection. Curr Opinion Immunol 2002; 14: 103-10.
33. Means TK, Golenbock DT, Fenton MJ. Structure and function of Toll-like receptor proteins. Life Sci 2000; 68: 241-58.
34. Rietschel ET, Kirikae T, Schade FU, Mamet U, Schmidt G, Loppnow H, et al. Bacterial endotoxin: molecular relationships of structure to activity and function. FASEB J 1994; 8: 217-25.
35. Preston A, Mandrell RE, Gibson BW, Apicella MA. The lipooligosaccharides of pathogenic Gram-negative bacteria. Crit Rev Microbiol 1996; 22(3): 139-80.
36. Wilkinson SG. Bacterial lipopolysaccharides - themes and variations. Prog Lipid Res 1996; 35(3): 283-343.
37. Holst O, Ulmer AJ, Brade H, Flad H-D, Rietschel ET. Biochemistry and cell biology of bacterial endotoxins. FEMS Immunol Med Microbiol 1996; 16: 83-104.
38. Raetz CR, Whitfield C. Lipopolysaccharide endotoxins. Annu Rev Biochem 2002; 71: 635-700.
39. Li L, Messas E, Batista EL, Jr, Levine RA, Amar S. Porphyromonas gingivalis infection accelerates the progression of atherosclerosis in a heterozygous apolipoprotein E-deficient murine model. Circulation 2002; 105(7): 861-7.
40. De Nardin E. The role of inflammatory and immunological mediators in periodontitis and cardiovascular disease. Annals of Periodontology 2001; 6(1): 30-40.
41. Kuramitsu HK, Kang IC, Qi M. Interaction of Porphyromonas gingivalis with host cells: implications for cardiovascular diseases. J Periodontol 2003; 74(1): 85-9.
42. Brandtzaeg P, Kierulf P, Gaustad P, Skulberg A, Bruun JN, Halvorsen S, et al. Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. J Infect Dis 1989; 159: 195-204.
43. Rice JB, Stoll LL, Li W-G, Denning GM, Weydert J, Charipar E, et al. Low level endotoxin induces potent inflammatory activation of human blood vessels: inhibition by statins. Arterioscler Thromb Vasc Biol 2003; 23: 1576-82.
44. Aiello RJ, Bourassa P-A, Lindsey S, Weng W, Natoli E, Rollins BJ, et al. Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 1999; 19: 1518-25.
45. Ben-Baruch A, Michiel DF, Oppenheim JJ. Signals and receptors involved in recruitment of inflammatory cells. J Biol Chem 1995; 270(20): 11703-6.
46. Larsen CG, Anderson AO, Appella E, Oppenheim JJ, Matsushima K. The neutrophil-activating protein (NAP-1) is also chemotactic for T lymphocytes. Science 1989; 243: 1464-6.
47. Gerszten RE, Garcia-Zepeda EA, Lim YC, Yoshida M, Ding HA, Gimbrone MA Jr, et al. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 1999; 398: 718-23.
48. Boisvert WA, Santiago R, Curtiss LK, Terkeltaub RA. A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. J Clin Invest 1998; 101(2): 353-63.
49. Yang X, Coriolan D, Murthy V, Schultz K, Golenbock DT, Beasley D. Proinflammatory phenotype of vascular smooth muscle cells: role of efficient Toll-like receptor 4 signaling. Am J Physiol Heart Circ Physiol 2005; 289(3): H1069-76.
50. Wiedermann CJ, Kiechl S, Dunzendorfer S, Schratzberger P, Egger G, Oberhollenzer F, et al. Association of endotoxemia with carotid atherosclerosis and cardiovascular disease. Prospective results from the Bruneck study. J Amer Coll Cardiol 1999; 34(7): 1975-81.
51. Kiechl S, Egger G, Mayr M, Wiedermann CJ, Bonora E, Oberhollenzer F, et al. Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study. Circulation 2001; 103: 1064-70.
52. Schratzberger P, Kiechl S, Dunzendorfer S, Kahler CM, Patsch JR, Willeit J, et al. Plasma-induced endothelial activation associated with incident atherosclerosis: prospective results from the Bruneck Study. J Cardiovase Risk 2000; 7(4): 285-91.
53. Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000; 25: 187-91.
54. Schwartz DA. The role of TLR4 in endotoxin responsiveness in humans. J Endotoxin Res 2001; 7(5): 389-93.
55. Kiechl S, Lorenz E, Reindl M, Wiedermann CJ, Oberhollenzer F, Bonora E, et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002; 347(3): 185-92.
56. Ameziane N, Beillat T, Verpillat P, Chollet-Martin S, Aumont MC, Seknadji P, et al. Association of the Toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events. Arterioscler Thromb Vasc Biol 2003; 23(12): e61-4.
57. Kolek MJ, Carlquist JF, Muhlestein JB, Whiting BM, Horne BD, Bair TL, et al. Toll-like receptor 4 gene Asp299Gly polymorphism is associated with reductions in vascular inflammation, angiographic coronary artery disease, and clinical diabetes. Am Heart J 2004; 148(6): 1034-40.
58. Balistreri CR, Candore G, Colonna-Romano G, Lio D, Caruso M, Hoffmann E, et al. Role of Toll-like receptor 4 in acute myocardial infarction and longevity. JAMA 2004; 292(19): 2339-40.
59. Yang IA, Holloway JW, Ye S. TLR4 Asp299Gly polymorphism is not associated with coronary artery stenosis. Atherosclerosis 2003; 170(1): 187-90.
60. Netea MG, Hijmans A, van Wissen S, Smilde TJ, Trip MD, Kullberg BJ, et al. Toll-like receptor-4 Asp299Gly polymorphism does not influence progression of atherosclerosis in patients with familial hypercbolesterolaemia. Eur J Clin Invest 2004; 34(2): 94-9.
61. Norata GD, Garlaschelli K, Ongari M, Raselli S, Grigore L, Benvenuto F, et al. Effect of the Toll-like receptor 4 (TLR-4) variants on intima-media thickness and monocyte-derived macrophage response to LPS. J Intern Med 2005; 258(1): 21-7.
62. Oyama J, Blais C Jr, Liu X, Pu M, Kobzik L, Kelly RA, et al. Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice. Circulation 2004; 109(6): 784-9.
63. Lehr H-A, Sagban TA, Ihling C, Zahringer U, Hungerer K-D, Blumrich M, et al. Immunopathogenesis of atherosclerosis: endotoxin accelerates atherosclerosis in rabbits on hypercholesterolemic diet. Circulation 2001; 104: 914-20.
64. Ostos MA, Recalde D, Zakin MM, Scott-Algara D. Implication of natural killer T cells in atherosclerosis development during a LPS-induced chronic inflammation. FEBS Lett 2002; 519(1-3): 23-9.
65. Wright SD, Burton C, Hernandez M, Hassing H, Montenegro J, Mundt S, et al. Infectious agents are not necessary for murine atherogenesis. J Exp Med 2000; 191(8): 1437-42.
66. Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol 2004; 172(5): 2731-8.
67. Beutler B, Milsark IW, Cerami TC. Passive immunization against cachectin/ tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985; 229(4716): 869-71.
68. Bachofen M, Weibel ER. Structural alterations of lung parenchyma in the adult respiratory distress syndrome. Clin Chest Med 1982; 3(1): 35-56.
69. Jungi TW, Adler H, Adler B, Thony M, Krampe M, Peterhans E. Inducible nitric oxide synthase of macrophages. Present knowledge and evidence for species-specific regulation. Vet Immunol Immunopathol 1996; 54(1-4): 323-30.
70. Dirami G, Massaro D, Clerch LB. Regulation of lung manganese superoxide dismutase: species variation in response to lipopolysaccharide. Am J Physiol 1999; 276(5 Pt 1): L705-8.
71. Dorger M, Jesch NK, Rieder G, Hirvonen MR, Savolainen K, Krombach F, et al. Species differences in NO formation by rat and hamster alveolar macrophages in vitro. Am J Respir Cell Mol Biol 1997; 16(4): 413-20.
72. Heyes MP, Saito K, Chen CY, Proescholdt MG, Nowak TS Jr, Li J, et al. Species heterogeneity between gerbils and rats: quinolinate production by microglia and astrocytes and accumulations in response to ischemic brain injury and systemic immune activation. J Neurochem 1997; 69(4): 1519-29.
73. Redl H, Bahrami S, Schlag G, Traber DL. Clinical detection of LPS and animal models of endotoxemia. Immunobiology 1993; 187(3-5): 330-45.
74. Poltorak A, Riccairdi-Castagnoli P, Citterio S, Beutler B. Physical contact between lipopolysaccharide and toll-like receptor 4 revealed by genetic complementation. PNAS 2000; 97(5): 2163-7.
75. Golenbock DT, Hampton RY, Qureshi N, Takayama K, Raetz CR. Lipid A-like molecules that antagonize the effects of endotoxins on human monocytes. J Biol Chem 1991; 266(29): 19490-8.
76. Hajjar AM, Ernst RK, Tsai JH, Wilson CB, Miller SI. Human Toll-like receptor 4 recognizes host-specific LPS modifications. Nat Immunol 2002; 3(4): 354-9.
77. Lien E, Means TK, Heine H, Yoshimura A, Kusumoto S, Fukase K, et al. Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. J Clin Invest 2000; 105(4): 497-504.
78. Akashi S, Nagai Y, Ogata H, Oikawa M, Fukase K, Kusumoto S, et al. Human MD-2 confers on mouse Toll-like receptor 4 species-specific lipopolysaccharide recognition. Int Immunol 2001; 13(12): 1595-9.
79. Kawasaki K, Gomi K, Nishijima M. Cutting edge: Gln22 of mouse MD-2 is essential for species-specific lipopolysaccharide mimetic action of taxol. J Immunol 2001; 166(1): 11-4.
80. Poltorak A, He X, Smirnova I, Liu MY, Huffel CV, Du X, et al. Defective LPS signaling in CeH/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998; 292: 2085-8.
81. Yu B, Wright SD. Catalytic properties of lipopolysaccharide (LPS) binding protein. Transfer of LPS to soluble CD14. J Biol Chem 1996; 271(8): 4100-5.
82. Fenton MJ, Golenbock D. LPS-binding proteins and receptors. J. Leukocyte Biol. 1998; 64: 25-32.
83. Read TE, Harris HW, Grunfeld C, Feingold KR, Kane JP, Rapp JH. The protective effect of serum lipoproteins against bacterial lipopolysaccharide. Eur Heart J 1993; 14 (Suppl K): 125-9.
84. Van Bossuyt H, De Zanger RB, Wisse E. Cellular and subcellular distribution of injected lipopolysaccharide in rat liver and its inactivation by bile salts. J Hepatol 1988; 7(325-327).
85. Flegel WA, Wölpl A, Männel D, Northoff H. Inhibition of endotoxin-induced activation of human monocytes by human lipoproteins. Infect Immun 1989; 57(7): 2237-45.
86. Feingold KR, Funk JL, Moser AH, Shigenaga JK, Rapp JH, Grunfeld C. Role for circulating lipoproteins in protection from endotoxin toxicity. Infect Immun 1995; 63(5): 2041-6.
87. Levine DM, Parker TS, Donnelly TM, Walsh A , Rubin AL. In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci USA 1993; 90: 12040-4.
88. Parker TS, Levine DM, Chang JCC, Laxer J, Coffin CC, Rubin AL. Reconstituted high-density lipoprotein neutralizes Gram-negative bacterial lipopolysaccharides in human whole blood. Infect Immun 1995; 63(1): 253-8.
89. Viriyakosol S, Kirkland TN. The N-terminal half of membrane CD14 is a functional cellular lipopolysaccharide receptor. Infect Immun 1996; 64(2): 653-6.
90. Antal-Szalmas P. Evaluation of CD14 in host defence. Eur J Clin Invest 2000; 30(2): 167-79.
91. Pugin J, Heumann ID, Tomasz A, Kravchenko VV, Akamatsu Y, Nishijima M, et al. CD14 is a pattern recognition receptor. Immunity 1994; 1(6): 509-16.
92. Hoebe K, Georgel P, Rutschmann S, Du X, Mudd S, Crozat K, et al. CD36 is a sensor of diacylglycerides. 2005; 433(7025): 523-7.
93. Viriyakosol S, Kirkland TN. A region of human CD14 required for lipopolysaccharide binding. J Biol Chem 1995; 270(1): 361-8.
94. Golenbock DT, Liu Y, Millham FH, Freeman MW, Zoeller RA. Surface expression of human CD14 in Chinese hamster ovary fibroblasts imparts macrophage-like responsiveness to bacterial endotoxin. J Biol Chem 1993; 268(29): 22055-9.
95. Amar J, Ruidavets JB, Bal Dit Sollier C, Bongard V, Boccalon H, Chamontin B, et al. Soluble CD14 and aortic stiffness in a population-based study. J Hypertens 2003; 21(10): 1869-77.
96. Jersmann HPA, Hii CST, Hodge GL, Ferrante A. Synthesis and surface expression of CD14 by human endothelial cells. Infect Immun 2001; 69(1): 479-85.
97. Bazil V, Baudys M, Hilgert I, Stefanova I, Low MG, Zbrozek J, et al. Structural relationship between the soluble and membrane-bound forms of human monocyte surface glycoprotein CD14. Mol Immunol 1989; 26: 657-62.
98. Tapping RI, Tobias PS. Soluble CD14-mediated cellular responses to lipopolysaccharide. Chem Immunol 2000; 74: 108-21.
99. Jersmann HP. Time to abandon dogma: CD14 is expressed by non-myeloid lineage cells. Immunol Cell Biol 2005; 83(5): 462-7.
100. Pugin J, Schurer-Maly CC, Leturcq D, Moriarty A, Ulevitch RJ, Tobias PS. Lipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipopolysaccharide-binding protein and soluble CD14. Proc Natl Acad Sci USA 1993; 90(7): 2744-8.
101. Froon AHM, Dentener MA, Greve JWM, Ramsay G, Buurman WA. Lipolysaccharide toxicity-regulating proteins in bacteremia. J Infect Dis 1995; 171: 1250-7.
102. Hayashi J, Masaka T, Ishikawa I. Increased levels of soluble CD14 in sera of periodontitis patients. Infect Immun 1999; 67(1): 417-20.
103. Landmann R, Zimmerli W, Sansano S, Link S, Hahn A, Glauser MP, et al. Increased circulating soluble CD14 is associated with high mortality in gram-negative shock. J Infect Dis 1995; 171: 639-44.
104. Lamping N, Dettmer R, Schröder NWJ, Pfeil D, Hallatschek W, Burger R. LPS-binding protein protects mice from septic shock caused by LPS or Gram-negative bacteria. J Clin Invest 1998; 101(10): 2065-71.
105. Pasterkamp G, Van Keulen JK, De Kleijn DP. Role of Toll-like receptor 4 in the initiation and progression of atherosclerotic disease. Eur J Clin Invest 2004; 34(5): 328-34.
106. Johnson GB, Brunn GJ, Platt JL. Activation of mammalian Toll-like receptors by endogenous agonists. Crit Rev Immunol 2003; 23(1-2): 15-44.
107. Lee JY, Sohn KH, Rhee SH, Hwang D. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J Biol Chem 2001; 276(20): 16683-9.
108. Hwang D. Modulation of the expression of cyclooxygenase-2 by fatty acids mediated through toll-like receptor 4-derived signaling pathways. FASEB J 2001; 15(14): 2556-64.
109. Chow JC, Young DW, Golenbock DT, Christ WJ, Gusovsky F. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem 1999; 274(16): 10689-92.
110. Shimazu R, Akashi S, Ogata H, Nagai Y, Fukudome K, Miyake K, et al. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 1999; 189(11): 1777-82.
111. Viriyakosol S, Tobias PS, Kitchens RL, Kirkland TN. MD-2 binds to bacterial lipopolysaccharide. J Biol Chem 2001; 276(41): 38044-51.
112. Nagai Y, Akashi S, Nagafuku M, Ogata M, Iwakura Y, Akira S, et al. Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol 2002; 3(7): 667-72.
113. Gioannini TL, Teghanemt A, Zhang D, Coussens NP, Dockstader W, Ramaswamy S, et al. Isolation of an endotoxin-MD-2 complex that produces Toll-like receptor 4-dependent cell activation at picomolar concentrations. Proc Natl Acad Sci USA 2004; 101(12): 4186-91.
114. da Silva Correia J, Soldau K, Christen U, Tobias PS, Ulevitch RJ. Lipopolysaccharide is in close proximity to each of the proteins in its membrane receptor complex. transfer from CD14 to TLR4 and MD-2. J Biol Chem 2001; 276(24): 21129-35.
115. Akira S, Yamamoto M, Takeda K. Role of adapters in Toll-like receptor signalling. Biochem Soc Trans 2003; 31(Pt 3): 637-42.
116. Medzhitov R, Preston-Hurlburt P, Kopp E, Stadlen A, Chen C, Ghosh S, et al. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell 1998; 2(2): 253-8.
117. Horng T, Barton GM, Flavell RA, Medzhitov R. The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors. Nature 2002; 420(6913): 329-33.
118. Yamamoto M, Sato S, Hemmi H, Sanjo H, Uematsu S, Kaisho T, et al. Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4. Nature 2002; 420(6913): 324-9.
119. Kawai T, Adachi O, Ogawa T, Takeda K, Akira S. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 1999; 11: 115-22.
120. Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA 2004; 101(29): 10679-84.
121. Bjorkbacka H, Kunjathoor VV, Moore KJ, Koehn S, Ordija CM, Lee MA, et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med 2004; 10(4): 416-21.
122. Wesche H, Henzel WJ, Shillinglaw W, Li S, Cao Z. MyD88: An adapter that recruits IRAK to the IL-1 receptor complex. Immunity 1997; 7: 837-47.
123. Suzuki N, Suzuki S, Duncan GS, Millar DG, Wada T, Mirtsos C, et al. Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4. Nature 2002; 416(6882): 750-6.
124. Suzuki N, Suzuki S, Yeh WC. IRAK-4 as the central TIR signaling mediator in innate immunity. Trends Immunol 2002; 23(10): 503-6.
125. Baldwin AS, Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996; 14: 649-83.
126. Landmann R, Wesp M, Obrecht JP. Cytokine regulation of the myeloid glycoprotein CD14. Pathobiology 1991; 59(3): 131-5.
127. Fearns C, Ulevitch RJ. Effect of recombinant interleukin-1 beta on murine CD14 gene expression in vivo. Shock 1998; 9(3): 157-63.
128. Fearns C, Loskutoff DJ. Role of tumor necrosis factor alpha in induction of murine CD14 gene expression by lipopolysaccharide. Infect Immun 1997; 65(11): 4822-31.
129. Liu S, Morris SM Jr, Nie S, Shapiro RA, Billiar TR. cAMP induces CD14 expression in murine macrophages via increased transcription. J Leukoc Biol 2000; 67(6): 894-901.
130. Ruppert J, Schutt C, Ostermeier D, Peters JH. Down-regulation and release of CD14 on human monocytes by IL-4 depends on the presence of serum or GM-CSF. Adv Exp Med Biol 1993; 329: 281-6.
131. Lauener RP, Goyert SM, Geha RS, Vercelli D. Interleukin 4 down-regulates the expression of CD14 in normal human monocytes. Eur J Immunol 1990; 20(11): 2375-81.
132. Kruger M, Van de Winkel JG, De Wit TP, Coorevits L, Ceuppens JL. Granulocyte-macrophage colony-stimulating factor down-regulates CD14 expression on monocytes. Immunology 1996; 89(1): 89-95.
133. Hamon G, Mulloy RH, Chen G, Chow R, Birkenmaier C, Horn JK. Transforming growth factor-beta 1 lowers the CD14 content of monocytes. J Surg Res 1994; 57(5): 574-8.
134. Nockher WA, Scherberich JE. Expression and release of the monocyte lipopolysaccharide receptor antigen CD14 are suppressed by glucocorticoids in vivo and in vitro. J Immunol 1997; 158(3): 1345-52.
135. Wheeler MD, Thurman RG. Up-regulation of CD14 in liver caused by acute ethanol involves oxidant-dependent AP-1 pathway. J Biol Chem 2003; 278(10): 8435-41.
136. McIntyre KM, Dixon PS, Krock LP, Piepmeier EH, Jr. The influence of hyperbaric oxygenation on leukocyte viability and surface protein expression. Aviat Space Environ Med 1997; 68(12): 1129-33.
137. Magrinat G, Mason SN, Shami PJ, Weinberg JB. Nitric oxide modulation of human leukemia cell differentiation and gene expression. Blood 1992; 80(8): 1880-4.
138. Landmann R, Knopf HP, Link S, Sansano S, Schumann RR, Zimmerli W. Human monocytes CD14 is upregulated by lipopolysaccharide. Infect Immun. 1996; 64: 1762-9.
139. Hopkins HA, Monick MM, Hunninghake GW. Lipopolysaccharide upregulates surface expression of CD14 on human alveolar macrophages. Am J Physiol 1995; 269(6 Pt 1): L849-54.
140. Matsuura K, Ishida T, Setoguchi M, Higuchi Y, Akizuki S, Yamamoto S. Upregulation of mouse CD14 expression in Kupffer cells by lipopolysaccharide. J Exp Med 1994; 179(5): 1671-6.
141. Liu S, Khemlani LS, Shapiro RA, Johnson ML, Liu K, Geller DA, et al. Expression of CD14 by hepatocytes: upregulation by cytokines during endotoxemia. Infect Immun 1998; 66(11): 5089-98.
142. Saluk-Juszczak J, Wachowicz B, Kaca W. Endotoxins stimulate generation of superoxide radicals and lipid peroxidation in blood platelets. Microbios 2000; 103(404): 17-25.
143. Frantz S, Kobzik L, Kim YD, Fukazawa R, Medzhitov R, Lee RT, et al. Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest 1999; 104(3): 271-80.
144. Faure E, Thomas L, Xu H, Medvedev AE, Equils O, Arditi M. Bacterial lipopolysaccharide and IFN-γ induce Toll-like receptor 2 and Toll-like receptor 4 expression in human endothelial cells: role of NF-κB activation. J Immunol 2001; 166: 2018-24.
145. An H, Yu Y, Zhang M, Xu H, Qi R, Yan X, et al. Involvement of ERK, p38 and NF-kappaB signal transduction in regulation of TLR2, TLR4 and TLR9 gene expression induced by lipopolysaccharide in mouse dendritic cells. Immunology 2002; 106(1): 38-45.
146. Wolfs TG, Buurman WA, van Schadewijk A, de Vries B, Daemen MA, Hiemstra PS, et al. In vivo expression to Tool-like receptor 2 and 4 by renal epithelial cells: IFN-gamma and TNF-alpha mediated up-regulation during inflammation. J Immunol 2002; 168(3): 1286-93.
147. Abreu MT, Arnold ET, Thomas LS, Gonsky R, Zhou Y, Hu B, et al. TLR4 and MD-2 expression is regulated by immune-mediated signals in human intestinal epithelial cells. J Biol Chem 2002; 277(23): 20431-7.
148. Williams DL, Ha T, Li C, Kalbfleisch JH, Schweitzer J, Vogt W, et al. Modulation of tissue Toll-like receptor 2 and 4 during the early phases of polymicrobial sepsis correlates with mortality. Crit Care Med 2003; 31(6): 1808-18.
149. Matsuguchi T, Musikacharoen T, Ogawa T, Yoshikai Y. Gene expressions of Toll-like receptor 2, but not Toll-like receptor 4, is induced by LPS and inflammatory cytokines in mouse macrophages. J Immunol 2000; 165(10): 5767-72.
150. Calandra T. Macrophage migration inhibitory factor and host innate immune responses to microbes. Scand J Infect Dis 2003; 35(9): 573-6.
151. Roger T, David J, Glauser MP, Calandra T. MIF regulates innate immune responses through modulation of Toll-like receptor 4. Nature 2001; 414(6866): 920-4.
152. Xu XH, Shah P, Faure E, Equils O, Thomas L, Fishbein MC, et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 2001; 104: 3103-8.
153. Matsumura T, Ito A, Takii T, Hayashi H, Onozaki K. Endotoxin and cytokine regulation of toll-like receptor (TLR) 2 and TLR4 gene expression in murine liver and hepatocytes. J Interferon Cytokine Res 2000; 20(10): 915-21.
154. Abreu MT, Fukata M, Arditi M. TLR signaling in the gut in health and disease. J Immunol 2005; 174(8): 4453-60.
155. Abreu MT, Vora P, Faure E, Thomas LS, Arnold ET, Arditi M. Decreased expression of Toll-like receptor-4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterial lipopolysaccharide. J Immunol 2001; 167(3): 1609-16.
156. Ortega-Cava CF, Ishihara S, Rumi MA, Kawashima K, Ishimura N, Kazumori H, et al. Strategic compartmentalization of Toll-like receptor 4 in the mouse gut. J Immunol 2003; 170(8): 3977-85.
157. Bsibsi M, Ravid R, Gveric D, van Noort JM. Broad expression of Toll-like receptors in the human central nervous system. J Neuropathol Exp Neurol 2002; 61(11): 1013-21.
158. Pivarcsi A, Koreck A, Bodai L, Szell M, Szeg C, Belso N, et al. Differentiation-regulated expression of Toll-like receptors 2 and 4 in HaCaT keratinocytes. Arch Dermatol Res 2004; 296(3): 120-4.
159. Methe H, Kim JO, Kofler S, Weis M, Nabauer M, Koglin J. Expansion of circulating Toll-like receptor 4-positive monocytes in patients with acute coronary syndrome. Circulation 2005; 111(20): 2654-61.
160. Monick MM, Yarovinsky TO, Powers LS, Butler NS, Carter AB, Gudmundsson G, et al. Respiratory syncytial virus up-regulates TLR4 and sensitizes airway epithelial cells to endotoxin. J Biol Chem 2003; 278(52): 53035-44.
161. Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 2002; 105(10): 1158-61.
162. Bozza M, Satoskar AR, Lin G, Lu B, Humbles AA, Gerard C, et al. Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J Exp Med 1999; 189(2): 341-6.
163. Strieter RM, Remick DG, Ham JM, Colletti LM, Lynch JP, 3rd, Kunkel SL. Tumor necrosis factor-alpha gene expression in human whole blood. J Leukoc Biol 1990; 47(4): 366-70.
164. Dickensheets HL, Freeman SL, Smith MF, Donnelly RP. Interleukin-10 upregulates tumor necrosis factor receptor type-II (p75) gene expression in endotoxin-stimulated human monocytes. Blood 1997; 90(10): 4162-71.
165. Harrington JR. The role of MCP-1 in atherosclerosis. Stem Cells 2000; 18: 65-6.
166. Reape TJ, Groot PHE. Chemokines and atherosclerosis. Atherosclerosis 1999; 147: 213-25.
167. Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 1998; 2: 275-81.
168. 2 activation in human neutrophils. Immunology 1992; 75: 157-63.
169. Ley K. Molecular mechanisms of leukocyte recruitment in the inflammatory process. Cardiovasc Res 1996; 32(4): 733-42.
170. Albelda SM, Smith CW, Ward PA. Adhesion in molecules and inflammatory injury. Faseb J 1994; 8(8): 504-12.
171. Brown EJ. Adhesive interactions in the immune system. Trends Cell Biol 1997; 7: 289-95.
172. Shen Y, Sultana C, Arditi M, Kim KS, Kalra VK. Endotoxin-induced migration of monocytes and PECAM-1 phosphorylation are abrogated by PAF receptor antagonists. Am J Physiol 1998; 275(3 Pt 1): E479-86.
173. Newman PJ. The role of PECAM-1 in vascular cell biology. Ann N Y Acad Sci 1994; 714: 165-74.
174. Pohlman TH, Stanness KA, Beatty PG, Ochs HD, Harlan JM. An endothelial cell surface factor(s) induced in vitro by lipopolysaccharide, interleukin 1, and tumor necrosis factor-alpha increases neutrophil adherence by a CDw 18-dependent mechanism. J Immunol 1986; 136(12): 4548-53.
175. Tedder TF, Steeber DA, Chen A, Engel P. The selectins: vascular adhesion molecules. Faseb J 1995; 9(10): 866-73.
176. Hyakushima N, Mitsuzawa H, Nishitani C, Sano H, Kuronuma K, Konishi M, et al. Interaction of soluble form of recombinant extracellular TLR4 domain with MD-2 enables lipopolysaccharide binding and attenuates TLR4-mediated signaling. J Immunol 2004; 173(11): 6949-54.
177. Divanovic S, Trompette A, Atabani SF, Madan R, Golenbock DT, Visintin A, et al. Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105. Nat Immunol 2005; 6(6): 571-8.
178. Yang QW, Mou L, Lv FL, Zhu PF, Wang ZG, Jiang JX, et al. Novel TLR4-antagonizing peptides inhibit LPS-induced release of inflammatory mediators by monocytes. Biochem Biophys Res Commun 2005; 329(3): 846-54.
179. Cluff CW, Baldridge JR, Stover AG, Evans JT, Johnson DA, Lacy MJ, et al. Synthetic Toll-Like Receptor 4 Agonists Stimulate Innate Resistance to Infectious Challenge. Infect Immun 2005; 73(5): 3044-52.
180. Bartels C, Maass M, Bein G, Malisius R, Brill N, Bechtel JF, et al. Detection of Chlamydia pneumoniae but not cytomegalovirus in occluded saphenous vein coronary artery bypass grafts. Circulation 1999; 99(7): 879-82.
181. Kuo CC, Jackson LA, Campbell LA, Grayston JT. Chlamydia pneumoniae (TWAR). Clin Microbiol Rev 1995; 8(4): 451-61.
182. Gaydos CA, Summersgill JT, Sahney NN, Ramirez JA, Quinn TC. Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial
183. Dechend R, Maass M, Gieffers J, Dietz R, Scheidereit C, Leutz A, et al. Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-kappaB and induces tissue factor and PAI-1 expression: a potential link to accelerated arteriosclerosis. Circulation 1999; 100(13): 1369-73.
184. Grayston JT. Antibiotic treatment of atherosclerotic cardiovascular disease. Circulation 2003; 107(9): 1228-30.
185. Grayston JT, Kronmal RA, Jackson LA, Parisi AF, Muhlestein JB, Cohen JD, et al. Azithromycin for the secondary prevention of coronary events. N Engl J Med 2005; 352(16): 1637-45.
186. Andraws R, Berger JS, Brown DL. Effects of antibiotic therapy on outcomes of patients with coronary artery disease: a meta-analysis of randomized controlled trials. JAMA 2005; 293(21): 2641-7.
187. Anderson JL. Infection, antibiotics, and atherothrombosis - end of the road or new beginnings? N Engl J Med 2005; 352(16): 1706-9.
188. Beck JD, Eke P, Heiss G, Madianos P, Couper D, Lin D, et al. Periodontal disease and coronary heart disease: a reappraisal of the exposure. Circulation 2005; 112(1): 19-24.
189. Fowler EB, Breault LG, Cuenin MF. Periodontal disease and its association with systemic disease. Mil Med 2001; 166(1): 85-9.
190. Iwamoto Y, Nishimura F, Soga Y, Takeucki K, Kurihara M, Takashiba S, et al. Antimicrobial periodontal treatment decreases serum C-reactive protein, tumor necrosis factor-alpha, but not adiponectin levels in patients with chronic periodontitis. J Periodontol 2003; 74(8): 1231-6.
191. Pussinen PJ, Vilkuna-Rautiainen T, Alfthan G, Palosuo T, Jauhiainen M, Sundvall J, et al. Severe periodontitis enhances macrophage activation via increased serum lipopolysaccharide. Arterioscler Thromb Vasc Biol 2004; 24(11): 2174-80.
192. Ross SD, Allen IE, Connelly JE, Korenblat BM, Smith ME, Bishop D, et al. Clinical outcomes in statin treatment trials: a meta-analysis. Arch Int Med 1999; 159: 1793-802.
193. Bellosta S, Ferri N, Bernini F, Paoletti R, Corsini A. Non-lipid-related effects of statins. Ann Med 2000; 32: 164-76.
194. Palinski W. New evidence for beneficial effects of statins unrelated to lipid lowering. Arterioscler Thromb Vasc Biol 2001; 21: 3-5.
195. Werner N, Nickenig G, Laufs U. Pleiotropic effects of HMG-CoA reductase inhibitors. Basic Res Cardiol 2002; 97(2): 105-16.
196. Sparrow CP, Burton CA, Hernandez M, Mundt S, Hassing H, Patel S, et al. Sinivastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 2001; 21: 115-21.
197. Diomede L, Albani D, Sottocorno M, Donati MB, Bianchi M, Fruscella P, et al. In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler Thromb Vasc Biol 2001; 21: 1327-32.
198. Inoue I, Goto S-i, Mizotani K, Awata T, Mastunaga T, Kawai S-i, et al. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect. Reduction of mRNA levels for interleukin-1β, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor α (PPARα) in primary endothelial cells. Life Sci 2000; 67: 863-76.
199. Crisby M. Modulation of the inflammatory process by statins. Drugs Today Barc 2003; 39(2): 137-43.
200. Lefer DJ. Statins as potent antiinflammatory drugs. Circulation 2002; 106(16): 2041-2.
201. Pahan K, Sheikh FG, Namboodiri AMS, Singh I. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest 1997; 100(11): 2671-9.
202. Takeuchi S, Kawashima S, Rikitake Y, Ueyama T, Inoue N, Hirata K, et al. Cerivastatin suppresses lipopolysaccharide-induced ICAM-1 expression through inhibition of Rho GTPase in BAEC. Biochem Biophys Res Commun 2000; 269(1): 97-102.
203. Ando H, Takamura T, Ota T, Nagai Y, Kobayashi K. Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis. J Pharmacol Exp Ther 2000; 294(3): 1043-6.
204. Merx MW, Liehn EA, Janssens U, Lutticken R, Schrader J, Hanrath P, et al. HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Circulation 2004; 109(21): 2560-5.
205. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001; 103(15): 1933-5.
206. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. Jama 2001; 286(1): 64-70.
207. Schonbeck U, Gerdes N, Varo N, Reynolds RS, Horton DB, Bavendiek U, et al. Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells. Circulation 2002; 106(23): 2888-93.
208. Cipollone F, Mezzetti A, Porreca E, Di Febbo C, Nutini M, Fazia M, et al. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation 2002; 106(4): 399-402.
209. Wong B, Lumma WC, Smith AM, Sisko JT, Wright SD, Cai TQ. Statins suppress THP-1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranylation. J Leukoc Biol 2001; 69(6): 959-62.
210. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: Implications for plaque stabilization. Circulation 2001; 103(7): 926-33.
211. Dichtl W, Dulak J, Frick M, Alber HF, Schwarzacher SP, Ares MP, et al. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2003; 23(1): 58-63.
212. Casey PJ. Protein lipidation in cell signaling. Science 1995; 268: 221-5.
213. Harris CM, Poulter CD. Recent studies of the mechanism of protein prenylation. Nat Prod Rep 2000; 17(2): 137-44.
214. Wagner AH, Köhler T, Rückscloss U, Just I, Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 2000; 20: 61-9.
215. Terkeltaub R, Solan J, Barry M Jr, Santoro D, Bokoch GM. Role of the mevalonate pathway of isoprenoid synthesis in IL-8 generation by activated monocytic cells. J Leukoc Biol 1994; 55(6): 749-55.
216. Stalker TJ, Lefer AM, Scalia R. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid. Br J Pharmacol 2001; 133(3): 406-12.
217. Wassmann S, Laufs U, Baumer AT, Muller K, Ahlbory K, Linz W, et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001; 37(6): 1450-7.
218. Rubio I, Wittig U,. Meyer C, Heinze R, Kadereit D, Waldmann H, et al. Farnesylation of Ras is important for the interaction with phosphoinositide 3-kinase γ. Eur J Biochem 1999; 266: 70-82.
219. Laufs U, Liao JK. Targeting Rho in cardiovascular disease. Circ Res 2000; 87(7): 526-8.
220. Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature 2002; 420(6916): 629-35.
221. Van Aelst L, D'Souza-Schorey C. Rho GTPases and signaling networks. Genes Dev 1997; 11(18): 2295-322.
222. Montaner S, Perona R, Saniger L, Lacal JC. Multiple signalling pathways lead to the activation of the nuclear factor kappaB by the Rho family of GTPases. J Biol Chem 1998; 273(21): 12779-85.
223. Perona R, Montaner S, Saniger L, Sanchez-Perez I, Bravo R, Lacal JC. Activation of the nuclear factor-kappaB by Rho, CDC42, and Rac-1 proteins. Genes Dev 1997; 11(4): 463-75.
224. Higashi M, Shimokawa H, Hattori T, Hiroki J, Mukai Y, Morikawa K, et al. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circ Res 2003; 93(8): 767-75.
225. Eto M, Kozai T, Cosentino F, Joch H, Luscher TF. Stalin prevents tissue factor expression in human endothelial cells: Role of Rho/Rho-kinase and Akt pathways. Circulation 2002; 105(15): 1756-9.
226. Hernandez-Perera O, Perez-Sala D, Soria E, Lamas S. Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells. Circ Res 2000; 87(7): 616-22.
227. Ito T, Ikeda U, Shimpo M, Ohki R, Takahashi M, Yamamoto K. et al. HMG-CoA reductase inhibitors reduce interleukin-6 synthesis in human vascular smooth muscle cells. Cardiovasc Drugs Ther 2002; 16(2): 121-6.
228. Methe H, Kim J-O, Kofler S, Nabauer M, Weis M. Statins decrease Toll-like receptor 4 expression and downstream signaling in human CD14+ monocytes. Arterioscler Thromb Vasc Biol 2005; 25(7): 1439-45.
229. Schaefer JR, Schweer H, Ikewaki K, Stracke H, Seyberth HJ, Kaffarnik H, et al. Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inbibition in healthy subjects and a patient with coronary artery disease. Atherosclerosis 1999; 144(1): 177-84.
230. Martin G, Duez H, Blanquart C, Berezowski V, Poulain P, Fruchart JC, et al. Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J Clin Invest 2001; 107(11): 1423-32.
231. Toth PP. High-density lipoprotein and cardiovascular risk. Circulation 2004; 109(15): 1809-12.
232. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res 2004; 95(8): 764-72.
233. Barter PJ. Cardioprotective effects of high-density lipoproteins: The evidence strengthens. Arterioscler Thromb Vasc Biol 2005; 25(7): 1305-6.
234. Emancipator K, Csako G, Elin RJ. In vitro inactivation of bacterial endotoxin by human lipoproteins and apolipoproteins. Infect Immun 1992; 60(2): 596-601.
235. Levels JHM, Abraham PR, van den Ende A, van Deventer SJH. Distribution and kinetics of lipoprotein-bound endotoxin. Infect Immun 2001; 69(5): 2821-8.
236. Pajkrt D, Doran JE, Koster F, Lerch PG, Arnet B, van der Poll T, et al. Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med 1996; 184: 1601-8.
237. Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ. Nuclear receptors and lipid physiology: opening the X-files. Science 2001; 294(5548): 1866-70.
238. Denning GM, Stoll LL. Peroxisome proliferator-activated receptors: potential therapeutic targets in lung disease? Pediatric Pulmonology 2005; In Press.
239. Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 2000; 49(10): 497-505.
240. Daynes RA, Jones DC. Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2002; 2(10): 748-59.
241. Blaschke F, Bruemmer D, Law RE. Will the potential of peroxisome proliferator-activated receptor agonists be realized in the clinical setting? Clin Cardiol 2004; 27(7 Suppl, 4): IV3-10.
242. Imamoto E, Yoshida N, Uchiyama K, Kuroda M, Kokura S, Ichikawa H, et al. Inhibitory effect of pioglitazone on expression of adhesion molecules on neutrophils and endothelial cells. Biofactors 2004; 20(1): 37-47.
243. Bocher V, Pineda-Torra I, Fruchart JC, Staels B. PPARs: transcription factors controlling lipid and lipoprotein metabolism. Ann N Y Acad Sci 2002; 967: 7-18.
244. Sugiyama H, Nonaka T, Kishumoto T, Komoriya K, Tsuji K, Nakahata T. Peroxisome proliferator-activated receptors are expressed in human cultured mast cells: a possible role of these receptors in negative regulation of mast cell activation. Eur J Immunol 2000; 30(12): 3363-70.
245. Tanaka T, Itoh H, Doi K, Fukunaga Y, Hosoda K, Shintani M, et al. Down regulation of peroxisome proliferator-activated receptorgamma expression by inflammatory cytokines and its reversal by thiazolidinediones. Diabetologia 1999; 42(6): 702-10.
246. Welch JS, Ricote M, Akiyama TE, Gonzalez FJ, Glass CK. PPAR-gamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. Proc Natl Acad Sci USA 2003; 100(11): 6712-7.
247. Blanquart C, Barbier O, Fruchart JC, Staels B, Glineur C. Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation. J Steroid Biochem Mol Biol 2003; 85(2-5): 267-73.
248. Murphy GJ, Holder JC. PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer. Trends Pharmacol Sci 2000; 21(12): 469-74.
249. Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W. The PPARalpha-leukotriene B4 pathway to inflammation control. Nature 1996; 384(6604): 39-43.
250. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med 2002; 53: 409-35.
251. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351(11): 1106-18.
252. Chen F, Wang M, O'Connor JP, He M, Tripathi T, Harrison LE. Phosphorylation of PPARgamma via active ERK 1/2 leads to its physical association with p65 and inhibition of NF-kappabeta. J Cell Biochem 2003; 90(4): 732-44.
253. Shu H, Wong B, Zhou G, Li Y, Berger J, Woods JW, et al. Activation of PPARalpha or gamma reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells. Biochem Biophys Res Commun 2000; 267(1): 345-9.
254. Meissner M, Stein M, Urbich C, Reisinger K, Suske G, Staels B, et al. PPAR(alpha) activators inhibit vascular endothelial growth factor receptor-2 expression by repressing Sp1-dependent DNA binding and transactivation. Circ Res 2004; 94(3): 324-32.
255. Delerive P, Martin-Nizard F, Chinetti G, Trottein F, Fruchart JC, Najib J, et al. Peroxisome proliferator-activated receptor activators inhibit thrombin- induced endothelin-1 production in human' vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res 1999; 85(5): 394-402.
256. Subbaramaiah K, Lin DT, Hart JC, Dannenberg AJ. Peroxisome proliferator-activated receptor gamma ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300. J Biol Chem 2001; 276(15): 12440-8.
257. Ricote M, Valledor AF, Glass CK. Decoding transcriptional programs regulated by PPARs and LXRs in the macrophage: effects on lipid homeostasis, inflammation, and atherosclerosis. Arterioscler Thromb Vasc Biol 2004; 24(2): 230-9.
258. Hammad H, de Heer HJ, Soullie T, Angeti V, Trottein F, Hoogsteden HC, et al. Activation of peroxisome proliferator-activated receptor-gamma in dendritic cells inhibits the development of eosinophilic airway inflammation in a mouse model of asthma. Am J Pathol 2004; 164(1): 263-71.
259. Ruiz-Velasco N, Dominguez A, Vega MA. Statins upregulate CD36 expression in human monocytes, an effect strengthened when combined with PPAR-gamma ligands Putative contribution of Rho GTPases in statin-induced CD36 expression. Biochem Pharmacol 2004; 67(2): 303-13.
260. Keen HL, Ryan MJ, Beyer A, Mathur S, Scheetz TE, Gackle BD, et al. Gene expression profiling of potential PPAR(gamma) target genes in mouse aorta. Physiol Genom 2004; 18(1): 33-42.
261. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 1998; 93(2): 229-40.
262. Landrier JF, Thomas C, Grober J, Duez H, Percevault F, Souidi M, et al. Stalin induction of liver fatty acid-binding protein (L-FABP) gene expression is peroxisome proliferator-activated receptor-alpha-dependent. J Biol Chem 2004; 279(44): 45512-8.
263. Libby P, Egan D, Skarlatos S. Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research. Circulation 1997; 96: 4095-103.
264. Kiechl S, Egger G, Mayr M, Wiedermann CJ, Bonora E, Oberhollenzer F, et al. Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study. Circulation 2001; 103(8): 1064-70.
265. Binder CJ, Horkko S, Dewan A, Chang MK, Kieu EP, Goodyear CS, et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med 2003; 9(6): 736-43.
266. Madjid M, Naghavi M, Litovsky S, Casscells SW. Influenza and Cardiovascular Disease: a New Opportunity for Prevention and the Need for Further Studies. Circulation 2003; 108(22): 2730-6.
267. Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med 1995; 123(7): 518-27.
268. Nichol KL, Wuorenma J, von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Intern Med 1998; 158(16): 1769-76.
269. Naghavi M, Barlas Z, Siadaty S, Naguib S, Madjid M, Casscells W. Association of influenza vaccination and reduced risk of recurrent myocardial infarction. Circulation 2000; 102(25): 3039-45.
270. Siscovick DS, Raghunathan TE, Lin D, Weinmann S, Arbogast P, Lemaitre RN, et al. Influenza vaccination and the risk of primary cardiac arrest. Am J Epidemiol 2000; 152(7): 674-7.
271. Zhou X, Robertson A-KL, Rudling M, Parini P, Hansson GK. Lesion development and response to immunization reveal a complex role for CD4 in atherosclerosis. Circ Res 2005; 96(4): 427-34.
272. Ameli S, Hultgardh-Nilsson A, Regnstrom J, Calara F, Yano J, Cercek B, et al. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 1996; 16(8): 1074-9.
273. Caligiuri G, Nicoletti A, Zhou X, Tornberg I, Hansson GK. Effects of sex and age on atherosclerosis and autoimmunity in apoEdeficient mice. Atherosclerosis 1999; 145(2): 301-8.
274. Kaisho T, Akira S. Toll-like receptors as adjuvant receptors. Biochim Biophys Acta 2002; 1589(1): 1-13.
275. Amati L, Cozzolongo K, Manghisi OG, Cuppone R, Pellegrino NM, Caccavo D, et al. The immune responsiveness in hepatitis C virus infected patients: effects of interferon-alfa/ribavirin combined treatment on the lymphocyte response with special reference to B cells. Curr Pharm Des 2004; 10(17): 2093-100.
276. Buemi M, Aloisi C, Fulvio F, Caccamo C, Cavallaro E, Crasci E, et al. Cardiorenal consequences of atherosclerosis and statins therapy: from the past to the future. Curr Pharm Des 2005; 11(30): 3973-84.
277. Furnkranz A, Leitinger N. Regulation of inflammatory responses by oxidized phospholipids: structure-function relationships. Curr Pharm Des 2004; 10(8): 915-21.